Related Experiment Video
Updated: Jul 19, 2026
08:49
Murine Prostate Micro-dissection and Surgical Castration
Published on: May 11, 2016
5alpha-reductase: history and clinical importance
Reviews in Urology
|September 21, 2006
Summary
5alpha-reductase (5AR) inhibitors like finasteride and dutasteride offer a new drug therapy for benign prostatic hyperplasia (BPH). These drugs reduce dihydrotestosterone (DHT), shrinking the prostate and relieving symptoms without typical side effects.
Area of Science:
- Endocrinology
- Urology
- Pharmacology
Background:
- Benign prostatic hyperplasia (BPH) treatment has shifted from surgery to drug therapy.
- Dihydrotestosterone (DHT) is crucial for prostate growth, unlike testosterone.
- Congenital 5alpha-reductase (5AR) deficiency highlighted DHT's role.
Purpose of the Study:
- To review the role of 5alpha-reductase (5AR) inhibitors in treating symptomatic benign prostatic hyperplasia (BPH).
- To discuss the mechanism of action and potential future applications of 5AR inhibitors.
Main Methods:
- Review of scientific literature on 5alpha-reductase (5AR) inhibitors and benign prostatic hyperplasia (BPH).
- Analysis of the hormonal pathways involving testosterone and dihydrotestosterone (DHT) in prostate growth.
- Evaluation of clinical outcomes and side effect profiles of 5AR inhibitor drugs.
Main Results:
- 5AR inhibitors (finasteride, dutasteride) effectively reduce intraprostatic DHT levels.
- DHT inhibition leads to prostate shrinkage and symptomatic relief in men with BPH.
- These drugs offer an alternative to surgery with fewer side effects than traditional androgen deprivation.
Conclusions:
- 5AR inhibitors represent a significant advancement in BPH pharmacotherapy.
- These drugs not only alleviate symptoms but may also modify the natural course of BPH.
- Potential future uses include prostate cancer chemoprevention and managing BPH complications.
Related Concept Videos
01:27Phase I Reactions: Reductive Reactions
Phase I biotransformation reductive reactions are chemical processes that modify drugs by introducing or revealing polar functional groups via reduction. Enzymes called reductases catalyze these reactions, playing a pivotal role in drug metabolism by transforming lipophilic drugs into more polar, water-soluble metabolites for easy excretion. An essential type of reductive reaction is the carbonyl group reduction, where aldehydes and ketones are reduced to alcohols. An example is the...
01:20Disorders of the Male Reproductive System
Men's health issues are increasingly recognized as significant, with several conditions posing common threats. Among these, testicular cancer is especially prevalent in younger men, particularly those aged 20 to 35 years. The disease often manifests as a painless mass in the testicles, sometimes accompanied by a sensation of heaviness or a dull ache.
Prostate disorders are another major concern. These conditions can impair urinary flow due to the prostate's location around the urethra. Symptoms...
Prostate disorders are another major concern. These conditions can impair urinary flow due to the prostate's location around the urethra. Symptoms...
01:22Adrenergic Antagonists: Pharmacological Actions of ɑ-Receptor Blockers
α-Adrenergic antagonists, known as α-blockers, exert their effects by inhibiting α-adrenoceptors, leading to specific physiological actions. α1-blockers and α2-blockers have distinct pharmacological actions and therapeutic applications.
α1-blockers: These drugs inhibit α1-adrenoceptors on smooth muscle cells, resulting in vasodilation. This vasodilation lowers blood pressure, making α1-blockers valuable in treating hypertension. Additionally, α1-blockers effectively address urinary obstruction...
α1-blockers: These drugs inhibit α1-adrenoceptors on smooth muscle cells, resulting in vasodilation. This vasodilation lowers blood pressure, making α1-blockers valuable in treating hypertension. Additionally, α1-blockers effectively address urinary obstruction...
01:11Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase
Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
01:17Adrenergic Antagonists: Chemistry and Classification of ɑ-Receptor Blockers
Adrenergic antagonists, or sympatholytics, inhibit adrenoceptor activation driven by catecholamines or agonists. Based on their adrenoceptor specificity, adrenergic blockers can be categorized into two primary groups: α-adrenergic blockers (α-blockers) and β-adrenergic blockers (β-blockers). α-blockers interact with α1 and α2 subtypes of α-adrenoceptors.
Nonselective α-blockers: Nonselective α-blockers contain haloalkylamine or imidazoline moieties. Phenoxybenzamine, with a haloalkylamine...
Nonselective α-blockers: Nonselective α-blockers contain haloalkylamine or imidazoline moieties. Phenoxybenzamine, with a haloalkylamine...
01:31Adrenergic Receptors: ɑ Subtype
Adrenoceptors are classified into α and ꞵ classes based on their potencies to catecholamine agonists. α-adrenoceptors show the following order of catecholamine potency:
Adrenaline ≥ Noradrenaline >> Isoprenaline
α-adrenoceptors are further divided into α1 and α2-adrenoceptors.
α1-Adrenoceptors: These receptors are located postsynaptically on the effector organs and cause constriction of smooth muscle mediated by activation of phospholipase C—inositol-1,4,5-trisphosphate...
Adrenaline ≥ Noradrenaline >> Isoprenaline
α-adrenoceptors are further divided into α1 and α2-adrenoceptors.
α1-Adrenoceptors: These receptors are located postsynaptically on the effector organs and cause constriction of smooth muscle mediated by activation of phospholipase C—inositol-1,4,5-trisphosphate...